01—Abstract
Summary
Summary of the 10-Q filed August 8, 2011. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (AXON), formerly known as TASER International, Inc., reported its financial results for the quarter ended June 30, 2011.
The company experienced a net sales increase of 10.9% to $21.2 milliona compared to the same period in the prior year, driven by strong international sales and the launch of the TASER X2. Despite the revenue growth, AXON reported a net loss of $2.3 million for the quarter, an increase from the $1.4 million net loss in Q2 2010. This widened loss was primarily due to a significant litigation judgment expense of $3.3 million related to an adverse jury verdict in the Turner v.
TASER International case, and a $1.4 millionb asset impairment charge for the Protector product line. The company's gross margin improved considerably, rising to 57.8% from 50.4% year-over-year, indicating better cost management and a favorable product mix. Operationally, AXON saw a decrease in SG&A expenses as a percentage of sales, reflecting cost-cutting measures.
However, research and development expenses also saw a reduction. The company maintained a strong liquidity position with $38.5 millionc in cash, cash equivalents, and investments as of June 30, 2011. AXON also continued its share repurchase program, investing $12.5 million in the quarter, and announced an additional $20 million repurchase authorization, signaling confidence in its financial stability despite the current period's net loss.
02—Key points
Key Highlights
- Net sales increased by 10.9% to $21.2 million for Q2 2011 compared to $19.1 million in Q2 2010.
- Gross margin improved significantly to 57.8% from 50.4% year-over-year, driven by favorable product mix and cost efficiencies.
- The company reported a net loss of $2.3 million for Q2 2011, an increase from the $1.4 million net loss in Q2 2010.
- A substantial litigation judgment expense of $3.3 million was recorded due to an adverse jury verdict in the Turner v. TASER International case.
- An asset impairment charge of $1.4 million was recognized for the abandonment of the Protector product line.
- Sales, General, and Administrative (SG&A) expenses decreased as a percentage of net sales to 42.8% from 52.2% year-over-year.
- The company generated $9.2 million in net cash from operating activities for the first six months of 2011, a significant turnaround from the $2.4 million used in the same period of 2010.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2011, Axon Enterprise, Inc. lost $0.11.
- Revenue$21.2M100.0%
- Cost of revenue−$9.0M42.3%
- Gross profit$12.2M57.7%
- Operating costs−$17.3M81.4%
- Operating income−$5.0M23.7%
- Interest, other & tax$2.7M12.8%
- Net income−$2.3M10.8%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2011filed August 8, 2011Financial Statements
Q2 FY2011 against Q2 FY2010
| Line item | Q2 FY2011Q2 FY2010 | Change |
|---|---|---|
| Revenue | $21.20M$19.12M | +10.9% |
| Cost of Revenue | $8.96M$9.49M | −5.6% |
| Gross Profit | $12.24M$9.63M | +27.1% |
| R&D Expenses | $2.79M$3.06M | −8.6% |
| SG&A Expenses | $9.07M$9.99M | −9.2% |
| Operating Income | -$5.02M-$3.44M | −46.0% |
| Net Income | -$2.29M-$1.36M | −68.8% |
| EPS (Basic) | $-0.04$-0.02 | −100.0% |
| EPS (Diluted) | $-0.04$-0.02 | −100.0% |
| Shares Outstanding (Basic) | 60.61M62.33M | −2.8% |
| Shares Outstanding (Diluted) | 60.61M62.33M | −2.8% |
05—Questions
Frequently Asked Questions
What drove the increase in net sales, and what was the overall sales performance?
Net sales increased by 10.9% to $21.2 million for the second quarter of 2011, compared to $19.1 million in the same period of 2010. This growth was primarily driven by an increase in individually significant international orders and domestic sales strengthened by the launch of the TASER X2, which contributed 7% to total net sales. Cartridge sales also saw a healthy increase of 12%.
Why did the company report a wider net loss despite increased sales?
The wider net loss of $2.3 million in Q2 2011, compared to $1.4 million in Q2 2010, was mainly due to significant one-time expenses. These included a $3.3 million litigation judgment expense stemming from an adverse jury verdict in the Turner v. TASER International case, and a $1.4 million asset impairment charge related to the decision to abandon the Protector product line. These extraordinary charges outweighed the revenue growth and improved gross margins.
How is the company managing its expenses and what is its liquidity position?
AXON has made progress in managing its expenses, with Sales, General, and Administrative (SG&A) expenses decreasing as a percentage of net sales to 42.8% from 52.2% in the prior year, reflecting cost-cutting measures. Research and development expenses also saw a reduction. The company maintains a strong liquidity position, ending the quarter with $38.5 million in cash, cash equivalents, and investments, and generated $9.2 million in operating cash flow for the first six months of 2011.
What is the status of the company's stock repurchase program?
AXON completed a $12.5 million stock repurchase program in the second quarter of 2011 and subsequently announced an additional repurchase authorization of up to $20 million in July 2011. This demonstrates management's confidence in the company's financial health and its commitment to returning value to shareholders.
06—Continue